Zhang Changpin, Pass Robert F
Department of Pediatrics, UAB School of Medicine, Children's Hospital CHB 309, 1600 7th Avenue South, Birmingham, AL 35233, USA.
Vaccine. 2004 Dec 9;23(4):507-10. doi: 10.1016/j.vaccine.2004.06.027.
Preabsorption of sera with cytomegalovirus (CMV) glycoprotein B (gB) prior to testing for CMV IgG antibody was evaluated for detection of CMV infection during CMV gB vaccine clinical trials. Although, 98.2% of 109 CMV gB vaccine recipients were seropositive with a standard assay, preabsorption of sera with gB reduced their CMV antibody to extremely low levels compared with subjects with CMV infection. One subject who acquired CMV during a vaccine trial was easily identified by gB-absorbed CMV IgG results. The gB-absorbed CMV IgG antibody assay is a promising approach for screening CMV gB vaccine trial participants for CMV infection.
在巨细胞病毒（CMV）糖蛋白B（gB）疫苗临床试验期间，为检测CMV感染，对检测CMV IgG抗体之前用CMV糖蛋白B（gB）进行血清预吸收的情况进行了评估。尽管在109名CMV gB疫苗接种者中，98.2%通过标准检测呈血清阳性，但与CMV感染受试者相比，用gB进行血清预吸收可将其CMV抗体降至极低水平。一名在疫苗试验期间感染CMV的受试者通过gB吸收后的CMV IgG结果很容易被识别出来。gB吸收后的CMV IgG抗体检测是一种很有前景的方法，可用于筛查CMV gB疫苗试验参与者是否感染CMV。
